Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H24N2O2S.C2H6O3S |
| Molecular Weight | 466.614 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCS(O)(=O)=O.CCN(CC)CCNC1=CC=C(CO)C2=C1C(=O)C3=C(S2)C=CC=C3
InChI
InChIKey=MFJJATAOPXFYNI-UHFFFAOYSA-N
InChI=1S/C20H24N2O2S.C2H6O3S/c1-3-22(4-2)12-11-21-16-10-9-14(13-23)20-18(16)19(24)15-7-5-6-8-17(15)25-20;1-2-6(3,4)5/h5-10,21,23H,3-4,11-13H2,1-2H3;2H2,1H3,(H,3,4,5)
| Molecular Formula | C20H24N2O2S |
| Molecular Weight | 356.482 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C2H6O3S |
| Molecular Weight | 110.132 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Hycanthone is a thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. It was clinically available for the treatment of human schistosomiasis. Anti-helmintic action relies on its ability to inhibit worm monoamine oxidase and cholinesterases. Hycanthone produced immediate side effects such as hepatotoxicity and gastrointestinal disturbances, and was consequently withdrawn. Hycanthone inhibits apurinic endonuclease-1 (APE1) by direct protein binding. Hycanthone was used in the 1980s as antitumor agents, it was pulled out of Phase II trials.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: UniProtKB: Q71SU7 (Carboxylic ester hydrolase) |
|||
Target ID: GO:0097621 |
|||
Target ID: CHEMBL5619 |
80.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Hycanthone Approved Usehuman schistosomiasis |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Long-term hepatocellular effects of hycanthone and of two other anti-Schistosomal drugs in mice infected with Schistosoma mansoni. | 1976 Jun |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
| The NIH-NIAID schistosomiasis resource center. | 2008 Jul 30 |
|
| Mefloquine--an aminoalcohol with promising antischistosomal properties in mice. | 2009 |
|
| Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. | 2009 Aug 18 |
|
| Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. | 2009 Jul 14 |
|
| RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. | 2010 Oct 19 |
|
| Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. | 2010 Sep 27 |
|
| Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Patents
Sample Use Guides
Human schistosomiasis: single intramuscular dose (3.0, 2.5, 2.0, 1.5, and 1.0 mg/kg body weight).Unresectable pancreatic cancer: hycanthone was administered 60 mg/m2 intravenously within 2 to 4 hr during each day of the 5-day course of infusions during the first and fifth weeks of radiation therapy.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:29:23 GMT 2023
by
admin
on
Fri Dec 15 18:29:23 GMT 2023
|
| Record UNII |
IOB67KGQ3N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40214487
Created by
admin on Fri Dec 15 18:29:23 GMT 2023 , Edited by admin on Fri Dec 15 18:29:23 GMT 2023
|
PRIMARY | |||
|
IOB67KGQ3N
Created by
admin on Fri Dec 15 18:29:23 GMT 2023 , Edited by admin on Fri Dec 15 18:29:23 GMT 2023
|
PRIMARY | |||
|
152365
Created by
admin on Fri Dec 15 18:29:23 GMT 2023 , Edited by admin on Fri Dec 15 18:29:23 GMT 2023
|
PRIMARY | |||
|
64265-18-5
Created by
admin on Fri Dec 15 18:29:23 GMT 2023 , Edited by admin on Fri Dec 15 18:29:23 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |